Sandoz Group (OTCMKTS:SDZNY) Upgraded to “Strong-Buy” at Erste Group Bank

Posted by Brian Himes on Aug 29th, 2026

Erste Group Bank upgraded shares of Sandoz Group (OTCMKTS:SDZNY – Free Report) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

Separately, Barclays raised shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Four investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Sandoz Group currently has a consensus rating of “Strong Buy”.

Get Our Latest Report on SDZNY

Sandoz Group Trading Down 3.0%

Shares of Sandoz Group stock opened at $85.14 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.77 and a current ratio of 1.18. The business has a 50 day moving average of $85.86 and a 200 day moving average of $83.75. Sandoz Group has a 52 week low of $55.42 and a 52 week high of $94.15.

Sandoz Group Company Profile

(Get Free Report)

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.